The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients

S. Zanussi, P. De Paoli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The initial idea that potent antiretroviral therapies could eradicate HIV infection within a few years of treatment has been recently challenged by the demonstration that the viral reservoir persists in the peripheral blood and in the lymphoid tissue. For this reason, an alternative approach based on the use of interleukin-2 has been developed. This cytokine, in fact, may be able to activate infected cells, promoting viral integration and replication, making HIV susceptible to antiretroviral treatments; this fact may ultimately contribute to the eradication of the virus itself. The measurement of the viral reservoir appears therefore essential to monitor the effects of combination therapies. We summarize here the technical approaches that have been used to quantitatively assess the HIV reservoir. We also show that the prolonged use of IL-2 in association with antiretroviral drugs promotes a reduction of the viral reservoir, but is unable to eradicate HIV, even after two years of therapy. The available in vitro and in vivo data do not exclude the fact that IL-2 may have a future in the treatment of HIV infection, though new therapeutic approaches using different strategies are required to clarify this issue. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

Original languageEnglish
Pages (from-to)316-320
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume54
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

Interleukin-2
HIV
Therapeutics
HIV Infections
Virus Integration
Lymphoid Tissue
Cytokines
Viruses
Pharmaceutical Preparations

Keywords

  • HIV
  • Interleukin-2
  • Molecular biology
  • Viral reservoir

ASJC Scopus subject areas

  • Pharmacology

Cite this

The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients. / Zanussi, S.; De Paoli, P.

In: Biomedicine and Pharmacotherapy, Vol. 54, No. 6, 2000, p. 316-320.

Research output: Contribution to journalArticle

@article{a5af1d58ac6942139819e32f344cac3d,
title = "The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients",
abstract = "The initial idea that potent antiretroviral therapies could eradicate HIV infection within a few years of treatment has been recently challenged by the demonstration that the viral reservoir persists in the peripheral blood and in the lymphoid tissue. For this reason, an alternative approach based on the use of interleukin-2 has been developed. This cytokine, in fact, may be able to activate infected cells, promoting viral integration and replication, making HIV susceptible to antiretroviral treatments; this fact may ultimately contribute to the eradication of the virus itself. The measurement of the viral reservoir appears therefore essential to monitor the effects of combination therapies. We summarize here the technical approaches that have been used to quantitatively assess the HIV reservoir. We also show that the prolonged use of IL-2 in association with antiretroviral drugs promotes a reduction of the viral reservoir, but is unable to eradicate HIV, even after two years of therapy. The available in vitro and in vivo data do not exclude the fact that IL-2 may have a future in the treatment of HIV infection, though new therapeutic approaches using different strategies are required to clarify this issue. (C) 2000 Editions scientifiques et medicales Elsevier SAS.",
keywords = "HIV, Interleukin-2, Molecular biology, Viral reservoir",
author = "S. Zanussi and {De Paoli}, P.",
year = "2000",
doi = "10.1016/S0753-3322(00)80054-2",
language = "English",
volume = "54",
pages = "316--320",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "6",

}

TY - JOUR

T1 - The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients

AU - Zanussi, S.

AU - De Paoli, P.

PY - 2000

Y1 - 2000

N2 - The initial idea that potent antiretroviral therapies could eradicate HIV infection within a few years of treatment has been recently challenged by the demonstration that the viral reservoir persists in the peripheral blood and in the lymphoid tissue. For this reason, an alternative approach based on the use of interleukin-2 has been developed. This cytokine, in fact, may be able to activate infected cells, promoting viral integration and replication, making HIV susceptible to antiretroviral treatments; this fact may ultimately contribute to the eradication of the virus itself. The measurement of the viral reservoir appears therefore essential to monitor the effects of combination therapies. We summarize here the technical approaches that have been used to quantitatively assess the HIV reservoir. We also show that the prolonged use of IL-2 in association with antiretroviral drugs promotes a reduction of the viral reservoir, but is unable to eradicate HIV, even after two years of therapy. The available in vitro and in vivo data do not exclude the fact that IL-2 may have a future in the treatment of HIV infection, though new therapeutic approaches using different strategies are required to clarify this issue. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

AB - The initial idea that potent antiretroviral therapies could eradicate HIV infection within a few years of treatment has been recently challenged by the demonstration that the viral reservoir persists in the peripheral blood and in the lymphoid tissue. For this reason, an alternative approach based on the use of interleukin-2 has been developed. This cytokine, in fact, may be able to activate infected cells, promoting viral integration and replication, making HIV susceptible to antiretroviral treatments; this fact may ultimately contribute to the eradication of the virus itself. The measurement of the viral reservoir appears therefore essential to monitor the effects of combination therapies. We summarize here the technical approaches that have been used to quantitatively assess the HIV reservoir. We also show that the prolonged use of IL-2 in association with antiretroviral drugs promotes a reduction of the viral reservoir, but is unable to eradicate HIV, even after two years of therapy. The available in vitro and in vivo data do not exclude the fact that IL-2 may have a future in the treatment of HIV infection, though new therapeutic approaches using different strategies are required to clarify this issue. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

KW - HIV

KW - Interleukin-2

KW - Molecular biology

KW - Viral reservoir

UR - http://www.scopus.com/inward/record.url?scp=0033855855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033855855&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(00)80054-2

DO - 10.1016/S0753-3322(00)80054-2

M3 - Article

C2 - 10989965

AN - SCOPUS:0033855855

VL - 54

SP - 316

EP - 320

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 6

ER -